In addition, single-nucleotide polymorphisms (SNPs) located near or within the MIR2052HG gene locus are associated with the recurrence of breast cancer in patients treated with aromatase inhibitors as adjuvant therapy, suggesting that these SNPs in MIR2052HG are promising biomarkers that can be used to identify patients in whom aromatase inhibitors would be an appropriate therapy [98]. This evidence concerns the gene CYP19A1 and breast cancer.